Results unveiled at ASCO show a substantial benefit to J&J and Legend’s cell therapy Carvykti over standard drug regimens for the blood cancer.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,